Antibe Therapeutics Inc., - CEO, Dan Legault
CEO, Dan Legault
Source: @AntibeThera, Twitter
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Antibe Therapeutics (TSXV:ATE) has made it onto the TSX Venture 50™ list for the second year in a row.
  • The TSX Venture 50™ ranks the top performing companies on the TSX Venture Exchange.
  • The 2020 list ranked the top ten performers in five different industry sectors.
  • Antibe Therapeutics ranked 5th in the Clean Technology & Life Sciences category.
  • Antibe’s share price is up 1.59 per cent, with shares currently trading at $0.64 apiece.

Pharmaceutical company Antibe Therapeutics (ATE) has made it onto the TSX Venture 50™ list for a second consecutive year.

The TSX Venture 50™ is a list which ranks the top fifty performing companies on the TSX Venture Exchange.

The fifty companies consist of the ten best performers from five different industry sectors. Those sectors are Energy, Mining, Technology, Diversified Industries, and Clean Technology & Life Sciences. 

The companies who made it onto the list did so based on their market capitalisation growth, share price appreciation, and trading volume during the 2019 calendar year. 

This year, Antibe Therapeutics ranked 5th out of the ten companies in the Clean Technology & Life Sciences category.

Antibe CEO, Dan Legault, commented on the ranking. “It’s exciting to be recognised as a TSX Venture top performer for the second year in a row. We believe this award reflects a growing awareness of the best-in-class potential of our drug pipeline.”

“We hope to continue this success for our shareholders, as we complete our lead drug’s final Phase 2 trial, expand partnering activities and evolve into a Phase 3 company.”

Antibe’s share price is up 1.59 per cent, with shares currently trading at $0.64 apiece at 9:54am EST.

More From The Market Herald

" Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Revive Therapeutics (RVV) announced an update of its Food and Drug Administration (FDA) phase three clinical trial for Bucillamine.
The Market Herald Video

" BioVaxys (CSE:BIOV) signs binding term sheet for distribution of Papilocare in the U.S.

BioVaxys Technology Corp. (BIOV) has signed a binding term sheet with Procare Health Iberia, S.L. of Barcelona, Spain.

" Satellos Bioscience (TSXV:MSCL) announces OTCQB listing

Common shares of Satellos Bioscience (MSCL) have commenced trading on the OTCQB Venture Market (OTCQB) under the symbol MSCLF.
Innocan Pharma - CEO Iris Bincovish

" Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Innocan Pharma’s (INNO) patent application, which claims cannabinoid-based topical compositions can treat psoriasis of the scalp, has reached the national phase.